Skip to main content

'Relief to poor': MNC patent on costly TB drug rejected, to 'help' generic production

By A Representative 

On March 23, 2023, the Indian Patent Office (IPO) rejected pharma company Janssen’s application for an extension of its patent on bedaquiline, a drug used in the treatment of tuberculosis patients. The verdict that came just a day ahead of World Tuberculosis Day was celebrated by health activists and tuberculosis survivors in India.
Janssen, owned by multinational Johnson and Johnson, applied for an extension of their original patent on bedaquiline on the basis of having discovered a new formulation. According to Indian law, in order to be granted a patent extension in such a situation, the manufacturer has to show that the new formulation leads to an enhanced therapeutic effect. Janssen repeatedly failed to prove that in the case of bedaquiline salt formulation.
If the patent on bedaquiline had been extended, public and family budgets would have remained burdened by unjustifiable high costs of the drug. Bedaquiline is an important drug for TB patients on many counts. The older TB drugs include injectables such as kanamycin, which have severe side effects including permanent hearing loss. On the other hand, bedaquiline is an oral drug with much higher safety and efficacy profile.
Bedaquiline was the first new tuberculosis drug in forty years when it was approved by the US Food and Drug Administration in 2012. According to the most recent Global Tuberculosis Report, in 2021, India recorded 119,000 cases of multidrug resistant tuberculosis and over half a million deaths caused by the disease.
Priyam Lizmary Cherian, an intellectual property lawyer who argued the case at the IPO, said that the decision should ease the generic production of bedaquiline, making safe and effective treatment more accessible. “India, being a generic production hub, can count on companies being able to pick up production after the original patent expires in July 2023,” she said.
Widely recognized as a disease of the poor, tuberculosis is generally not a prominent field in Big Pharma research and development, although it affects the lives of hundreds of thousands in the Global South. In 2021, the money invested in this field globally was not even half of what a UN High Level Meeting identified as a target.
---
Source: Peoples Dispatch / Globetrotter News Service

Comments

TRENDING

How strategic is India's commercial expansion in the Mediterranean?

By Vijay Prashad  On 26 October 2026, Greece’s foreign minister George Gerapetritis stood at the United Nations headquarters and rejected the maritime agreement between Turkey and Libya. Gerapetritis spoke on behalf of Greece of course, but also Bahrain, Cyprus, Egypt, the European Union, and the United Arab Emirates. Five days later, the Indian frigate INS Trishul entered Souda Bay in Crete as part of activities with the US Navy installation (Naval Support Activity) and with the NATO Maritime Interdiction Operational Training Centre. The sequence illuminates a developing strategic geography: India’s naval reach, its confrontation with Pakistan’s new Turkish partner, and its ambition to connect Indian capital to European markets increasingly converge in the eastern Mediterranean.

'No vacant geographical spaces’: CMs urged to protect the Ghats from energy infrastructure overload

By A Representative   A prominent power and climate policy analyst has urged the Chief Ministers of Maharashtra, Andhra Pradesh, and Karnataka to comprehensively reassess the rapid proliferation of large pumped storage projects in the ecologically fragile Western and Eastern Ghats. In a detailed representation, addressed to the three Chief Ministers with copies to the Prime Minister and the Union Minister for Environment, Forest and Climate Change, analyst Shankar Sharma warned that the current trajectory of energy storage development risks irreversible ecological and social damage.

Letter to Modi seeks cancellation of "coercive" anti-NGO order on foreign funding rules

By A Representative  Around 70 civil rights organizations have come together to strategize “a collective response to the stifling of civil society space” in the wake of the recent Government of India clampdown on NGOs, telling Prime Minister Narendra Modi that government steps are “coercive” in nature, are “without reasonable cause or due process”, and seek to “cripple” the ability of NGOs to “carry on their legitimate and sanctioned work.”